Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health, Inc.: Second Quarter and Year-to-Date Results
Repositioned the Company to create meaningful P+L operating leverage Dramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020 FY 2021 guidance: reiterate Adj. EBITDA of $10 million while reducing TYMLOS revenue from $250 to $240 million TYMLOS Q2, 2021
View HTML
Toggle Summary Radius Health Business Update
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3% vs. Q1, 2021 ATOM and wearABLe abaloparatide Phase 3 trial readouts remain on track for 2H, 2021 EU abaloparatide regulatory resubmission remains on schedule for Q4, 2021 Prader-Willi Syndrome (PWS) pivotal Phase 2/3 study to
View HTML
Toggle Summary CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011 505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studies Based on results, a single well controlled study could serve as the basis for marketing approval RAD011 had previously
View HTML
Toggle Summary Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021
BOSTON , July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m.
View HTML
Toggle Summary Radius Health Business Update
TYMLOS ® new patient adds in April: modest growth vs. previous 4-month trailing averages ~67% of new patients in April were initiated by a fracture focused bone health account Meaningful FDA guidance on generic peptide requirements published on May 19, 2021 Anticipate abaloparatide depot
View HTML
Toggle Summary Radius Health, Inc.: First Quarter 2021 Results
Total net revenue: $56 million vs. $48 million in Q1, 2020, +17% year-over-year TYMLOS ®   U.S. product net revenue: $45 million vs. $48 million in Q1, 2020, -6% year-over-year Significant operating leverage improvement: Q1, 2021 adjusted EBITDA: ($5) million vs.
View HTML
Toggle Summary Radius Health Business Update
Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020 Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destocking April, 2021 month-to-date new patient adds indicate significant patient growth Three pivotal studies: all remain on track for 2H, 2021
View HTML
Toggle Summary Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021
BOSTON , April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a
View HTML
Toggle Summary Radius Health Provides Update on Abaloparatide
Regulatory success achieved in Japan by partner Teijin Pharma Limited Ostabaro® approved for treatment of male & female OP patients at high risk of fracture Japan is currently the largest anabolic market in the world $10 million milestone to be generated from Japan approval EU: intend to re-file
View HTML
Toggle Summary Radius Health, Inc. Announces $175 Million Financing Transaction
Repurchases $112.2 million of principal amount of the 3.00% convertible notes due September 1, 2024 (“2024 Notes”), representing approximately 37% of the outstanding 2024 Notes Estimated excess cash proceeds of approximately $14.2 million will be added to the balance sheet Eliminates approximately
View HTML